López-Martínez LM, Loreto-Garibay O, González-Romero E, López-Domínguez P, Rodríguez-Palafox SG

Language: Spanish
References: 11
Page: 91-103
PDF size: 494.50 Kb.

ABSTRACT

Objetive: To measure blood levels of Cholesterol, Triglycerides and Range AA / EPA in school age children registered at PROSPERA program before and aft er eating fi sh twice a week for a period of 6 months in Colonia Constitution. Material and Methods: Quantitative research, prospective longitudinal intervention study with comparison group. Th e design of the database was made, captured and analyzed with Epi Info 7 soft ware (version 7.1.5.2) complementing the OpenEpi.com platform (version 3.03a). Results: 137 Blood samples were taken to record levels of cholesterol, triglycerides and Range AA / EPA in the studied children at baseline, fi nding dyslipidemia in 48.9% of them, in addition to cellular inflammation in 100%. Aft er 6 months, the intervention group decreased 4.9 AA / EPA ratio and found that the level of is high borderline cholesterol level is the one that is most impacted by the consumption of fi sh. Conclusions: Considering the results, we suggest to continue with other quantitative studies to measure the impact of seafood intake, fat control, and exercise in decreasing the rate of dyslipidemia and increase cognitive level in schools. It must be implemented in the state of Jalisco an action plan to ensure that schoolchildren consume 18 kg per capita per year of seafood, involving the Ministry of Education, Ministry of Health, Ministry of Rural Development and the Ministry of Economic Development with the participation of the municipalities of the state.

REFERENCES

1. Electronic Medicines Compendium (eMC). http: //www. medicines.org.uk/emc/medicine/10312 /indications. Accessed August 20, 2012.

2. US Food and Drug Administration. http://www.fda.gov. Accessed August 20, 2012.

3. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376(9740):540-550.

4. Bosch J, Gerstein HC, Dagenais GR, et al; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-318.

5. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events aft er myocardial infarction. N Engl J Med. 2010; 363(21):2015-2026.

6. Tavazzi L, Maggioni AP, Marchioli R, et al; GISSIHF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet. 2008;372(9645):1223- 1230.

7. European Review for Medical and Pharmacological Sciences 20012; 16: 1137-1154 B. SEARS, C. RICORDI* Infl ammation Research Foundation, Marblehead, MA, USA and *Diabetes Research Institute, University of Miami, Miami, FL, USA Role of fatty acids and polyphenols in infl ammatory gene transcription and their impact on obesity, metabolic syndrome and diabetes

8. Daniels SR, Greer FR; Committee on Nutrition Lipid screening and cardiovascular health in childhood Pediatrics. 2008 Jul;122(1):198-208.

9. S.S. Sun, R. Liang, T.T. Huang, S.R. Daniels, S. Arslanian and K. Liu et al., Childhood obesity predicts adult metabolic syndrome: the Fels Longitudinal Study, J Pediatr 2008; 152:191–200.

10. Yokoyama M, Origasa H, Matsuzaki M, et al; Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis. Lancet. 2007; 369(9567):1090- 1098.

11. NORMA Ofi cial Mexicana NOM-037-SSA2-2012, Para la prevención, tratamiento y control de las dislipidemias.